Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT02610413
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Laboratory Biomarker Analysis — OTHER
    Correlative studies

Study Details

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with hypertension receiving bevacizumab for breast cancer. Studying samples of germline DNA in the laboratory from patients with hypertension receiving bevacizumab for breast cancer may help doctors learn about changes that occur in DNA and identify biomarkers related to hypertension.

Key Dates

Start date
Mar 25, 2014
Status verified
Mar 2026
Primary completion
Jan 1, 2100
Completion
Jan 1, 2100

Study Design

Enrollment
354 participants (estimated)

Arms

  • Arm: Ancillary-Correlative (whole exome sequencing)
    Previously collected germline DNA samples are analyzed via whole exome sequencing.

Primary Outcome Measure

Identification of rare coding variants of large effect that predict the risk of bevacizumab-induced hypertension [ Time Frame: Baseline ]

Locations (1)

FacilityCityStateZIPSite coordinators
Eastern Cooperative Oncology GroupBostonMassachusetts02215
Bryan P. Schneider
[email protected]
317-274-6473
Bryan P. Schneider (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Eastern Cooperative Oncology Group· Boston, MA

Related Studies